Results 31 to 40 of about 104,921 (341)
Safety and patient satisfaction of abobotulinumtoxinA for aesthetic use. A systematic review [PDF]
, 2017 A systematic review of the published literature (from January 2000 to January 2016) to ascertain the safety of, and patient satisfaction with, the aesthetic use of abobotulinumtoxinA was conducted.
Cohen, Joel L, Scuderi, Nicolo'
core +1 more source
Safety and efficacy of a propofol and ketamine based procedural sedation protocol in children with cerebral palsy undergoing botulinum toxin A injections. [PDF]
, 2019 Background Pediatric patients with cerebral palsy (CP) often undergo intramuscular botulinum toxin (BoNT‐A) injections. These injections can be painful and may require procedural sedation.
Abu-Sultaneh, Samer +4 more
core +1 more source
Вестник войск РХБ защиты, 2023 Botulism is dangerous toxic infection caused by a toxin produced by the bacterium Clostridium botulinum. The mortality rate from botulism can reach 70% of all cases of illness in case of untimely initiation of treatment.
D. S. Yanov +5 more
doaj +1 more source
PLoS ONE, 2014 Botulinum neurotoxin (BoNT) is the most poisonous substances known and its eight toxin types (A to H) are distinguished by the inability of polyclonal antibodies that neutralize one toxin type to neutralize any of the other seven toxin types.
Nir Dover +5 more
doaj +1 more source
Toxins, 2013 Tetanus toxin, the product of Clostridium tetani, is the cause of tetanus symptoms. Tetanus toxin is taken up into terminals of lower motor neurons and transported axonally to the spinal cord and/or brainstem. Here the toxin moves trans-synaptically into
Bjørnar Hassel
doaj +1 more source
Immunogenicity of botulinum toxins [PDF]
Journal of Neural Transmission, 2012 Botulinum neurotoxins are formulated biologic pharmaceuticals used therapeutically to treat a wide variety of chronic conditions, with varying governmental approvals by country. Some of these disorders include cervical dystonia, post-stroke spasticity, blepharospasm, migraine, and hyperhidrosis.
Naumann, Markus +3 more
openaire +3 more sources
Journal of Rehabilitation Medicine, 2020 Objective: To evaluate the role of diagnostic nerve block in predicting the outcome of subsequent botulinum toxin type A treatment for spastic equinovarus foot due to chronic stroke. Design: Retrospective observational study.
Alessandro Picelli +6 more
doaj +1 more source
Service-based survey of dystonia in Munich [PDF]
, 2002 We performed a service-based epidemiological study of dystonia in Munich, Germany. Due to favourable referral and treatment patterns in the Munich area, we could provide confident data from dystonia patients seeking botulinum toxin treatment.
Ben-Shlomo, Y. +7 more
core +1 more source
Botulinum Toxin for Pain [PDF]
Drugs in R & D, 2008 Botulinum toxin (BTX) injection is being increasingly used 'off label' in the management of chronic pain. Data support the hypothesis of a direct analgesic effect of BTX, different to that exerted on muscle. Although the pain-reducing effect of BTX is mainly due to its ability to block acetylcholine release at the synapse, other effects on the nervous ...
Roberto, Casale, Valeria, Tugnoli
openaire +2 more sources
Botulinum toxin A for the Treatment of Overactive Bladder
Toxins, 2016 The standard treatment for overactive bladder starts with patient education and behavior therapies, followed by antimuscarinic agents. For patients with urgency urinary incontinence refractory to antimuscarinic therapy, currently both American Urological
Po-Fan Hsieh +4 more
doaj +1 more source